DR. REDDY'S LABORATORIES-ADR (RDY) Stock Price, Forecast & Analysis
USA - NYSE:RDY - US2561352038 - ADR
RDY Key Statistics, Chart & Performance
The current stock price of RDY is 13.96 USD. In the past month the price decreased by -5.36%. In the past year, price decreased by -1.69%.
RDY Latest News, Press Relases and Analysis
RDY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.46 | 967.00B | ||
| JNJ | JOHNSON & JOHNSON | 19.23 | 480.66B | ||
| MRK | MERCK & CO. INC. | 10.54 | 231.94B | ||
| PFE | PFIZER INC | 7.84 | 142.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.14 | 95.28B | ||
| ZTS | ZOETIS INC | 18.74 | 52.65B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.58 | 12.43B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.31 | 10.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.36 | 7.92B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.26B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.08B |
Related stock screener links
About RDY
Company Profile
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Company Info
DR. REDDY'S LABORATORIES-ADR
8-2-337, Road No.3 Banjara Hills
Hyderabad TELANGANA 500-034 IN
CEO: Erez Israeli
Employees: 27048
Phone: 914049002900
DR. REDDY'S LABORATORIES-ADR / RDY FAQ
What does DR. REDDY'S LABORATORIES-ADR do?
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Can you provide the latest stock price for DR. REDDY'S LABORATORIES-ADR?
The current stock price of RDY is 13.96 USD. The price increased by 0.14% in the last trading session.
Does RDY stock pay dividends?
DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.65%. The yearly dividend amount is currently 0.09.
What is the ChartMill technical and fundamental rating of RDY stock?
RDY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the ex-dividend date for RDY stock?
The next ex-dividend date for DR. REDDY'S LABORATORIES-ADR (RDY) is July 25, 2025.
Can you provide the growth outlook for DR. REDDY'S LABORATORIES-ADR?
The Revenue of DR. REDDY'S LABORATORIES-ADR (RDY) is expected to grow by 5.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for DR. REDDY'S LABORATORIES-ADR?
DR. REDDY'S LABORATORIES-ADR (RDY) has a market capitalization of 11.62B USD. This makes RDY a Large Cap stock.
RDY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RDY. When comparing the yearly performance of all stocks, RDY turns out to be only a medium performer in the overall market: it outperformed 41.43% of all stocks.
RDY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RDY. While RDY has a great profitability rating, there are some minor concerns on its financial health.
RDY Financial Highlights
Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.78. The EPS increased by 8.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| Debt/Equity | 0.03 |
RDY Forecast & Estimates
45 analysts have analysed RDY and the average price target is 15.04 USD. This implies a price increase of 7.74% is expected in the next year compared to the current price of 13.96.
For the next year, analysts expect an EPS growth of -5.63% and a revenue growth 5.28% for RDY